Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
26/03/2026 20:49
Nurexone Biologic Inc NRX.V: NUREXONE STRENGTHENS U.S. MANUFACTURING STRATEGY THROUGH EXO-TOP SUBLICENSE AGREEMENT NUREXONE BIOLOGIC INC - NO MONETARY CONSIDERATION OR SUBLICENSE FEES EXPECTED FOR EXO-TOP SUBLICENSE Source text: ID:nGNX1SvW8n Further company coverage: NRX.V
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement